| Lyme Disease |
1 |
1 |
| Primary Care |
0 |
0.99 |
| Travel Medicine |
0 |
0.43 |
| Antigens |
0 |
0.35 |
| New York |
0 |
0.23 |
| Post-Acute Sequelae of SARS-CoV-2 Infection |
0 |
0.23 |
| Texas |
0 |
0.23 |
| Weakness |
0 |
0.23 |
| Dermatitis |
0 |
0.18 |
| Arthralgia |
0 |
0.17 |
| Fixed Drug Eruptions |
0 |
0.17 |
| Skin and Soft Tissue Infection |
0 |
0.17 |
| Biologic Therapy |
0 |
0.14 |
| Bacteria |
0 |
0.12 |
| Blood |
0 |
0.12 |
| Borrelia Burgdorferi |
0 |
0.12 |
| Canada |
0 |
0.12 |
| Cellulitis |
0 |
0.12 |
| Contact Dermatitis |
0 |
0.12 |
| Dermatophytosis |
0 |
0.12 |
| Drug Eruption |
0 |
0.12 |
| Europe |
0 |
0.12 |
| Face |
0 |
0.12 |
| Fatigue |
0 |
0.12 |
| Fever |
0 |
0.12 |
| Food and Drug Administration (FDA) |
0 |
0.12 |
| Geographic Tongue |
0 |
0.12 |
| Granuloma Annulare |
0 |
0.12 |
| Lupus |
0 |
0.12 |
| Meningitis |
0 |
0.12 |
| New Jersey |
0 |
0.12 |
| Pain |
0 |
0.12 |
| Syncope |
0 |
0.12 |
| COVID-19 |
0 |
0.09 |
| Otolaryngology |
0 |
0.08 |
| Systemic Lupus Erythematosus |
0 |
0.08 |